Sirolimus-eluting stent showed better one-year outcomes than paclitaxel-eluting stent in a real life setting of coronary intervention in Koreans

International Journal of Cardiology

Volumn 117, Issue 1, 2007, Pages 31-36

  Suh, Jung Won ^a,b   Park, Jin Shik ^a,b   Cho, Hyun Jai ^a,b   Kim, Min Seok ^a,b   Kang, Hyun Jae ^a,b   Cho, Young Seok ^a,c   Koo, Bon Kwon ^a,b   Chung, Woo Young ^a,c   Youn, Tae Jin ^a,c   Chae, In Ho ^a,c   Choi, Dong Ju ^a,c   Kim, Hyo Soo ^a,b   Sohn, Dae Won ^a,b   Oh, Byung Hee ^a,b   Park, Young Bae ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Drug eluting stent; Outcome; Paclitaxel; Restenosis; Sirolimus; Target lesion revascularization

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG DELIVERY SYSTEMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KOREA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PACLITAXEL; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33947126928     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.03.009     Document Type: Article

References (17)

1. Morice M.C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
2. Moses J.W., Leon M.B., Popma J.J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
3. Schampaert E., Cohen E.A., Schluter M., et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (CSIRIUS). J Am Coll Cardiol 43 (2004) 1110-1115
4. Schofer J., Schluter M., Gershlick A.H., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
5. Grube E., Silber S., Hauptmann K.E., et al. TAXUS I: six- and twelve month results from a randomized, double-blind trial on a slowrelease paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
6. Colombo A., Drzewiecki J., Banning A., et al. Randomized study assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
7. Stone G.W., Ellis S.G., Cox D.A., et al. A polymer-based, paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
8. Valgimigli M., van Mieghem C.A., Ong A.T., et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 111 (2005) 1383-1389
9. Kastrati A., Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs. balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis. JAMA 293 (2005) 165-171
10. Werner G.S., Krack A., Schwarz G., et al. Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol 44 (2004) 2301-2306
11. Valgimigli M., Percoco G., Malaguti P., et al. Tirofiban and sirolimus-eluting stent vs. abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
12. Windecker S., Remondino A., Eberli F.R., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Eng J Med 353 (2005) 653-662
13. Dibra A., Kastrati A., Mehilli J., et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Eng J Med 353 (2005) 663-670
14. Kastrati A., Dibra A., Eberle S., et al. Sirolimus-eluting stents vs. paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
15. Braunwald E., Antman E., and Beasley J. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 106 (2002) 1893-1900
16. Ong A.T., Serruys P.W., Aoki J., et al. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45 (2005) 1135-1141
17. Morice M.C., Colombo A., Meier B., et al. Sirolimus vs. paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295 (2006) 895-904